Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

38.72 +1.63 (+4.39%)
Official Closing Price Updated: 4:10 PM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,381,542
Open 37.66
Bid (Size) 38.50 (600)
Ask (Size) 38.71 (800)
Prev. Close 37.09
Today's Range 37.00 - 39.22
52wk Range 18.21 - 38.37
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars ↗
Teva Pharmaceutical Industries (NYSE:TEVA) said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics... 
Via MarketBeat
News headline image
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire

Performance

YTD
+25.1%
+25.1%
1 Month
+5.3%
+5.3%
3 Month
+14.9%
+14.9%
6 Month
+31.4%
+31.4%
1 Year
+105.0%
+105.0%

More News

Read More
News headline image
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Launch of Offering of Senior Notes
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study ↗
Via MarketBeat
News headline image
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva (TEVA) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Why Teva Pharmaceutical Stock Surged This Week ↗
Via The Motley Fool
Topics Stocks
News headline image
Teva Pharmaceutical Industries Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%. ↗
Via The Motley Fool
News headline image
Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right. ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Study ↗
Via MarketBeat
News headline image
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
From Polpharma Biologics International AG
Via Business Wire
News headline image
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? ↗
Via The Motley Fool

Frequently Asked Questions

Is Teva Pharmaceutical Industries Limited Ordinary Shares publicly traded?
Yes, Teva Pharmaceutical Industries Limited Ordinary Shares is publicly traded.
What exchange does Teva Pharmaceutical Industries Limited Ordinary Shares trade on?
Teva Pharmaceutical Industries Limited Ordinary Shares trades on the New York Stock Exchange
What is the ticker symbol for Teva Pharmaceutical Industries Limited Ordinary Shares?
The ticker symbol for Teva Pharmaceutical Industries Limited Ordinary Shares is TEVA on the New York Stock Exchange
What is the current price of Teva Pharmaceutical Industries Limited Ordinary Shares?
The current price of Teva Pharmaceutical Industries Limited Ordinary Shares is 38.72
When was Teva Pharmaceutical Industries Limited Ordinary Shares last traded?
The last trade of Teva Pharmaceutical Industries Limited Ordinary Shares was at 09/14/26 04:10 PM ET
What is the market capitalization of Teva Pharmaceutical Industries Limited Ordinary Shares?
The market capitalization of Teva Pharmaceutical Industries Limited Ordinary Shares is 42.99B
How many shares of Teva Pharmaceutical Industries Limited Ordinary Shares are outstanding?
Teva Pharmaceutical Industries Limited Ordinary Shares has 43B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.